Alan P. Venook, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Alan P. Venook, MD

Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine (Hematology/Oncology), UCSF
Madden Family Distinguished Professorship in Medical Oncology and Translational Research, UCSF

Phone: (415) 353-9888 (appts)
Box 1705, UCSF
San Francisco, CA 94143-1705

View on UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics

Research Summary

I am a Professor of Medicine with experience and expertise in clinical trial design in gastrointestinal malignancies. I have written, led, and then authored four clinical trials within the US Intergroup and recently presented the results of a fifth. I am Chair of the Gastrointestinal Committee of the Alliance for Clinical Trials in Oncology; prior to that, I was the founding Chair of the NCI’s Hepatobiliary Task Force. I have served as mentor or co-mentor for NIH grants for Drs. Katherine Van Loon (KL2, UCSF), Chloe Atreya (K08,UCSF), Erin Van Blarigan (KL2, UCSF) Rebecca Miksad (K23, BI-Deaconess), and Abby Siegel (K23, Columbia). I have been a mentor or co-mentor on ASCO YIA’s for Drs. R. K. Kelley, Atreya, Van Loon, and John Gordan and have mentored / trained thought leaders in GI oncology including Emily Bergsland, Andrew Ko, Bert O’Neil, and Ghassan Abou-Alfa.

Education

Rutgers College, New Brunswick, New Jersey, BA, 1976, Biological Sciences
University of California San Francisco, MD, 1980, Medicine
University of California San Francisco, Internship, 1981, Internal Medicine
University of California, Davis, Residency, 1985, Internal Medicine
University of California San Francisco, Fellowship, 1987, Hematology/Oncology


Professional Experience

  • 1980
    Assistant Clinical Professor of Medicine, UCSF
  • 1994-2000
    Associate Professor of Clinical Medicine, UCSF
  • 1997-2004
    Director, Clinical Research Support Services Core, UCSF Comprehensive Cancer Center
  • 2004-2007
    Associate Chief, Division of Medical Oncology, UCSF
  • 2004- present
    Member, Executive Policy Group of the Human Research Protection Program
  • 2005-present
    Chairman, UCSF Committee on Human Research
  • 2005-present
    Chairman, Cancer Center Data Safety Monitoring Committee
  • 2008- 2010
    Director, Regulatory Knowledge and Support Program of the UCSF Clinical and Translational Science Institute
  • 2008-present
    Member, Research Administration Board
  • 2000-present
    Professor of Clinical Medicine, UCSF

Honors & Awards

  • 1999
    Mention-Colon Cancer-Medical Oncologist, Top Cancer Specialsts, Good Housekeeping
  • 1999
    Mention-Medical Oncology and Hematology, Top 425 Doctors in the Bay Area, San Francisco

Selected Publications

  1. NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. J Natl Compr Canc Netw. 2015 Nov; 13(11):1337-46.
    View on PubMed
  2. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 1; 33(34):4023-31.
    View on PubMed
  3. The value and effectiveness of angiogenesis inhibitors for colorectal cancer. Clin Adv Hematol Oncol. 2015 Sep; 13(9):561-3.
    View on PubMed
  4. Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others? J Clin Oncol. 2015 Nov 10; 33(32):3686-8.
    View on PubMed
  5. Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2015 Nov 1; 33(31):3598-607.
    View on PubMed
  6. A MULTICENTER, OPEN-LABEL PHASE II CLINICAL TRIAL OF COMBINED MEK PLUS EGFR INHIBITION FOR CHEMOTHERAPY-REFRACTORY ADVANCED PANCREATIC ADENOCARCINOMA. Clin Cancer Res. 2015 Aug 6.
    View on PubMed
  7. On the Verge: Immunotherapy for Colorectal Carcinoma. J Natl Compr Canc Netw. 2015 Aug; 13(8):970-8.
    View on PubMed
  8. Rectal Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13(6):719-28.
    View on PubMed
  9. Special Series: Advances in GI Cancer. J Clin Oncol. 2015 Jun 1; 33(16):1717-20.
    View on PubMed
  10. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015; 15(1):206.
    View on PubMed
  11. Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma. Liver Cancer. 2015 Mar; 4(2):115-25.
    View on PubMed
  12. Bevacizumab vs EGFR antibodies in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2015 Feb; 13(2):90-2.
    View on PubMed
  13. Clinical cancer advances 2015: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol. 2015 Mar 1; 33(7):786-809.
    View on PubMed
  14. Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors. J Clin Oncol. 2015 Mar 20; 33(9):1060-6.
    View on PubMed
  15. Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance). Clin Cancer Res. 2015 Mar 1; 21(5):1078-86.
    View on PubMed
  16. A Case Series of Patients with HER2-Overexpressed Primary Metastatic Gastroesophageal Adenocarcinoma. Anticancer Res. 2014 Dec; 34(12):7357-60.
    View on PubMed
  17. Generalizability of trial results to elderly medicare patients with advanced solid tumors (alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1).
    View on PubMed
  18. Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer. J Natl Cancer Inst. 2015 Jan; 107(1).
    View on PubMed
  19. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect. 2015 Mar; 4(1):9-17.
    View on PubMed
  20. Progression-free survival: helpful biomarker or clinically meaningless end point? J Clin Oncol. 2015 Jan 1; 33(1):4-6.
    View on PubMed

Go to UCSF Profiles, powered by CTSI